Welcome to our dedicated page for Cytodyn news (Ticker: CYDY), a resource for investors and traders seeking the latest updates and insights on Cytodyn stock.
CytoDyn Inc. (CYDY) is a clinical-stage biotechnology and oncology company whose news flow centers on the development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. Company announcements frequently highlight progress in solid tumor oncology, particularly metastatic triple-negative breast cancer (mTNBC) and metastatic colorectal cancer (mCRC), as well as broader CCR5-related research.
Investors following CYDY news can expect updates on clinical trial milestones, including Phase 2 studies in mCRC and planned Phase 2 proof-of-concept and combination trials in mTNBC. Press releases and shareholder letters describe retrospective survival analyses, PD-L1 upregulation findings, and the company’s “prime and pair” strategy that combines leronlimab with immune checkpoint inhibitors. Conference-related news often covers poster and oral presentations at major oncology meetings such as the San Antonio Breast Cancer Symposium, European Society for Medical Oncology events, and AACR specialty conferences.
CytoDyn’s news stream also includes corporate and regulatory developments. Recent items have addressed the resolution of government investigations, an agreement in principle to settle a securities class action lawsuit, and stockholder approval of amendments to increase authorized common shares. Financing updates, such as the Standby Equity Purchase Agreement with Yorkville, provide insight into how the company plans to support its clinical programs.
In addition, CytoDyn issues periodic letters to shareholders that summarize operational rebuilding, regulatory interactions, and collaborations with academic centers in areas like glioblastoma, Alzheimer’s disease, and HIV cure research. For readers tracking CYDY, this news page offers a consolidated view of scientific data releases, trial progress, financing arrangements, and governance actions that shape the company’s development trajectory.
CytoDyn (OTCQB: CYDY) announced dosing of the first patient in an Expanded Access Program (EAP) for leronlimab in triple-negative breast cancer on April 27, 2026. The EAP provides access for patients who exhausted options, will follow FDA guidelines, and aims to collect real-world biological insights including PD-L1 associations reported at AACR 2026.
The company engaged WEP Clinical to support patient ID, site coordination, and regulatory compliance; physician referrals are now open.
CytoDyn (OTCQB: CYDY) will host an investor webcast on April 30, 2026 at 1:00 p.m. PT to provide a corporate and clinical update on leronlimab.
Presenters include CEO Dr. Jacob P. Lalezari, Dr. Pashtoon M. Kasi, and CFO Robert E. Hoffman. A live Q&A will follow and a replay will be available for ~30 days.
CytoDyn (OTCQB: CYDY) presented new Phase 2 data at AACR 2026 showing early clinical and biomarker activity for leronlimab combined with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer (mCRC).
Key findings: CCR5 expression in 100% of pre-screened cases (N=33), median ctDNA declines ~70% by week 2 (evaluable N=19), no leronlimab-related DLTs, and dose escalation to 700 mg underway.
CytoDyn (OTCQB: CYDY) completed enrollment in its Phase 2 CLOVER study of leronlimab plus TAS-102 and bevacizumab in CCR5-positive, MSS relapsed/refractory metastatic colorectal cancer on April 21, 2026.
Just over 60 patients were enrolled across seven U.S. sites; the company plans treatment, follow-up, and topline data reporting to inform next development steps.
CytoDyn (OTCQB: CYDY) presented translational and clinical data at AACR 2026 showing that leronlimab (CCR5 inhibitor) induces PD-L1, modulates immune checkpoints, and associates with prolonged survival in metastatic triple-negative breast cancer (mTNBC).
In a retrospective cohort (N=28), PD-L1 induction in CTCs/CAMLs and higher dose or ICI combination correlated with better outcomes; 17.9% (5/28) remain alive beyond 60 months. Poster #1033 was presented April 19, 2026.
CytoDyn (OTCQB: CYDY) will present two posters at the American Association for Cancer Research Annual Meeting 2026, April 17–22 in San Diego. The presentations report preclinical and preliminary clinical data on leronlimab in metastatic triple-negative breast cancer and metastatic colorectal cancer.
Poster 1033 (April 19) examines PD-L1 induction and ICI survival in PD-L1 low mTNBC; Poster 6466 (April 21) presents preliminary phase 2 results of leronlimab with TAS-102 and bevacizumab in previously treated mCRC. Presentations will be posted under Publications & Posters after the meeting.
CytoDyn (OTCQB: CYDY) presented preclinical and translational data at the AACR Special Conference on Brain Cancer (March 23-25, 2026) showing leronlimab-mediated CCR5 inhibition enhances temozolomide and radiation responses in glioblastoma.
Findings: CCR5 is elevated in GBM tumor cores, associates with hypoxia/glycolysis and T-cell exhaustion, and leronlimab showed functional synergy with standard therapies; a pilot clinical study is planned. Poster #A002 presented March 23, 2026.
CytoDyn (OTCQB: CYDY) closed a $17.5 million financing on March 5, 2026 to fund further development of leronlimab, its CCR5-targeting humanized monoclonal antibody being evaluated in oncology indications including TNBC and mCRC.
Net proceeds will primarily support ongoing and planned clinical trials, regulatory engagement, data analysis, manufacturing readiness, compliance infrastructure, and general working capital, and are expected to fund operations into 2027.
CytoDyn (OTCQB: CYDY) presented preclinical, translational, and clinical data on leronlimab at AACR IO (Feb 18-21, 2026) exploring CCR5 blockade in metastatic triple-negative breast cancer (mTNBC).
Key points: mechanistic signals show increased PD-L1 and modulation of T-cell exhaustion; a pooled retrospective cohort (n=28) reported favorable safety and 5 of 28 patients alive after median follow-up >63 months.
CytoDyn (OTCQB: CYDY) announced that an anonymous benefactor committed funding to support an Expanded Access Program (EAP) for patients with triple‑negative breast cancer (TNBC) to receive leronlimab. The company engaged WEP Clinical as CRO and expects to open the program for patient referral in March 2026, subject to FDA allowance of a revised protocol submission. The EAP is intended for patients who have exhausted approved treatments and do not meet ongoing trial criteria, and the company says the program may provide opportunities to observe PD‑L1 induction after leronlimab with potential combination pathways with immune checkpoint inhibitors. Additional physician and patient information will be posted on the company website as the program rolls out.